Immunopharmacotherapy: Vaccination strategies as a treatment for drug abuse and dependence

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 2, 2009, Pages 199-205

  Moreno, Amira Y ^a   Janda, Kim D ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Catalytic antibodies; Cocaine; Monoclonal antibodies; Nicotine; Passive immunization; Vaccination

Indexed keywords

AMFEBUTAMONE; ANTIBODY; COCAINE; COCAINE SPECIFIC MONOCLONAL ANTIBODY GNC92H2; COCAINE VACCINE; NICOTINE; NICOTINE VACCINE; NICQB; TA NIC; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

ANTIBODY SPECIFICITY; BLOOD BRAIN BARRIER; COMPULSION; DIAGNOSTIC ACCURACY; DRUG ABUSE; DRUG DEPENDENCE TREATMENT; HUMAN; IMMUNOPHARMACOTHERAPY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SOCIAL PROBLEM;

COCAINE-RELATED DISORDERS; HUMANS; IMMUNOTHERAPY; TOBACCO USE DISORDER;

EID: 59649092315     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2009.01.015     Document Type: Review

References (63)

1. Baird T.J., Deng S.X., Landry D.W., et al. Natural and artificial enzymes against cocaine. I: Monoclonal antibody 15A10 and the reinforcing effect of cocaine in rats. J Pharmacol Exp Ther 295 (2000) 1127-1134
2. Berkowitz B., and Spector S. Evidence for active immunity to morphine in mice. Science 178 (1972) 1290-1292
3. Bonese K., Wainer B., Fitch F., Rothberg R., and Schuster C. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252 (1974) 708-710
4. Bunce C.J., Loudon P., Akers C., Dobson J., and Wood D. Development of vaccines to help treat drug dependence. Curr. Opin. Mol. Ther. (2003) 58-63
5. Carrera M.R., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., and Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature 378 (1995) 727-730
6. Carrera M.R., Ashley J.A., Zhou B., Wirsching P., Koob G.F., and Janda K.D. Cocaine vaccines: antibody protection againste relapse in a rat model. Proc Natl Acad Sci 97 (2000) 6202-6206
7. Carrera M.R., Ashley J.A., Wirsching P., Koob G.F., and Janda K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci 98 (2001) 1988-1992
8. Carrera M.R., Ashley J.A., Hoffman T.Z., Isomura S., Wirsching P., Koob G.F., et al. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem 12 (2004) 563-570
9. Carrera M.R., Kaufmann G.F., Mee J.M., Meijler M.M., Koob G.F., and Janda K.D. Treating cocaine addiction with viruses. Proc Natl Acad Sci USA 101 (2004) 10416-10421
10. Carrera M.R., Trigo J.M., Wirsching P., Roberts A., and Janda K.D. Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 81 (2005) 709-714
11. Celtic Pharma. Celtic Pharma reports preliminary results of phase 2 clinical trials with TA-CD, cocaine addiction vaccine (2006). http://www.celticpharma.com/news/pr/release_062106.pdf Retrieved September 23, 2008, from http://www.celticpharma.com/news/pr/release_062106.pdf
12. Celtic Pharma TA CD. Retrieved September 23, 2008, from http://www.celticpharma.com/theportfolio/ta-cd.html.
13. Cerny E.H., Levy R., Mauel J., et al. Preclinical development of a vaccine "against smoking". Onkologie 25 (2002) 406-411
14. Chasnoff I.J., Bruns W.J., Schnoll W.J., and Burns K.A. Cocaine use in pregnancy. New England Journal of Medicine 313 (1985) 666-669
15. Cowell S., Lee Y., et al. Exploring ramachandran and chi space: conformationally constrained amino acids and peptides in the design of bioactive polypeptide ligands. Current Med Chem 11 (2004) 2785-2798
16. Cytos Biotechnology Clinical Development CYT002-NicQb. (2006). Retrieved June 30, 2008, from http://www.cytos.com/doc/NicQb_June06_E_fv.pdf.
17. European Monitoring Centre for Drugs and Drug Addiction. EMCDDA Literature reviews - Treatment of problem cocaine use: a review of the literature (2007). http://www.emcdda.europa.eu/?nnodeid=18945 Lisbon: Section 3.1. Available online http://www.emcdda.europa.eu/?nnodeid=18945
18. Fox B.S., Kantak K.M., Edwards M.A., Black K.M., Bollinger B.K., et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2 (1996) 1129-1132
19. Guy B. The perfect mix: recent progress in adjuvant research. Nature Rev Microbio 5 (2007) 505-517
20. Hatsukami D., Rennard S., Jorenby D.E., et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78 (2005) 456-467
21. Hieda Y., Keyler D.E., Vandevoort J.T., et al. Active immunization alters the plasma nicotine concntration in rats. J Pharmacol Exp Ther 283 (1997) 1076-1081
22. Hieda Y., Keyler D.E., Ennifar S., Fattom A., and Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 22 (2000) 809-819
23. Hughes J.R., Shiffman S., Callas P., and Zhang J. A meta-analysis of the efficacy of over-the-counter nicotine replacement. Tob Control 12 (2003) 21-27
24. Ino A., Dickerson T.J., and Janda K.D. Positional linker effects in haptens for cocaine immunopharmacotherapy. Bioorg Med Chem Lett 17 (2007) 4280-4283
25. Isomura S., Wirsching P., and Janda K.D. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J Org Chem 66 (2001) 4115-4121
26. Jorenby D.E., Hays J.T., Rigotti N.A., Azoulay S., Watsky E.J., Williams K.E., et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Amer Med Assoc 296 (2006) 56-63
27. Kantak K.M. Vaccines against drugs of abuse: a viable treatment option?. Drugs (2003) 341-352
28. Kantak K.M., Collins S.L., Lipman E.G., et al. Evalutaion of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacol 148 (2000) 251-262
29. Kauer J.A., and Malenka R.C. Synaptic plasticity and addiciton. Nat Rev Neurosci (2007) 844-858
30. Keyler D.E., Soeman D., LeSage M.G., Calvin A.D., and Pentel P.R. Maternal vaccination against nicotine reduces nicotine distribution to fetal brain in rats. J Pharmacol Exp Ther 305 (2003) 587-592
31. Keyler D.E., Roiko S.A., Benlhabib E., et al. Monoclonoal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose and affinity response relationship. Drug Metab Dispos 33 (2005) 1056-1061
32. Keyler D.E., Roiko S.A., Earlye C.A., Murtaugh M.P., and Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8 (2008) 1589-1594
33. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 (1997) 52-58
34. Kosten T., and Owens M. Immunotherapy for the treatment of drug abuse. Pharmacol Ther (2005) 76-85
35. Kosten T.R., Rosen M., Bond J., et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20 (2002) 1196-1204
36. Landry D.W., Zhao K., Yang G.X., et al. Antibody-catalyzed degradation of cocaine. Science 259 (1993) 1899-1901
37. Le Sage M.G., Keyler D.E., and Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J 8 1 (2006) E65-E75
38. Malin D.H., Lake J.R., Lin A., et al. Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome. Pharmacol Biochem Behav 68 (2001) 87-92
39. Matsushita M., Hoffman T.Z., Ashley J.A., Zhou B., Wirsching P., and Janda K.D. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Med Chem Lett 11 (2001) 87-90
40. Maurer P., Jennings G.T., Willers J., et al. A therapeutic vaccine for nicotine dependece: preclinical efficacy and Phase I safety and immunogenicity. Eur J Immunol 35 (2005) 2031-2040
41. McKenzie K.M., Mee J.M., Rogers C.J., Hixon M.S., Kaufmann G., and Janda K.D. Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 365 (2007) 722-731
42. Meijler M.M., Matsushita M., Altobell L., Wirsching P., and Janda K.D. A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc 125 (2003) 7164-7165
43. Meijler M.M., Matsushita M., Wirsching P., and Janda K.D. Development of Immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 1 (2004) 77-89
44. Mets B., Winger G., Cabrera C., et al. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95 (1998) 10176-10181
45. Mokdad A.H., Marks J.S., Stroup D.F., and Gerberding J.L. Actual causes of death in the United States. J Amer Med Assoc 291 (2004) 1238-1245
46. Nabi Biopharmaceutical Clinical Trial Information. (2007). Retrieved June 30, 2008, from http://www.nabi.com/pipeline/clinicaltrials.php#3.
47. National Institute on Drug Abuse. NIDA research report-cocaine abuse and addiction (2004) NIH Publication No. 99-4342
48. Nekhayeva I.A., Nanovskaya T.V., Pentel P.R., Keyler D., et al. Effects of nicotine-specfiic antibodies, Nic311 and Nic-IgG, on the transfer of nicotine across the human placenta. Biochem Pharmacol 70 (2005) 1664-1672
49. Pentel P.R., Malin D.H., Ennifar S., et al. A nicotine-conjugate vaccine reduces nicotine distribution to brian and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 65 (2000) 191-198
50. Preti A. The treatment of cocaine abuse: problems and perspectives. Cocaine and Heroin Abuse Research (2006) 1-35
51. Redwan E.R., Larsen N.A., Zhou B., Wirsching P., Janda K.D., and Wilson I.A. Expression and characterization of a humanized cocaine-binding antibody. Biotechnol Bioeng 82 (2003) 612-618
52. Roiko S.A., Harris A.C., Keyler D.E., LeSage M.G., Zhang Y., and Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J Pharmacol Exp Ther 325 (2008) 985-993
53. Sanderson S.D., Cheruku S.R., Padmanilayam M.P., et al. Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 3 (2003) 137-146
54. Schabacker D.S., Kirschbaum K.S., and Segre M. Exploring the feasibility of anti-idiotypic cocaine vaccine: analysis of the specificity of anticocaine antibodies (Ab1) capable of inducing Ab2beta anti-idiotypic antibodies. Immunology 100 (2000) 48-56
55. Singer L.T., Arendt R., Minnes S., Farkas K., Salvator A., Kirchner L., et al. Cognititve and motor outcomes of cocaine-exposed infants. J Am Med Assoc 287 (2002) 1952-1960
56. Spector S. Quantitative determination of morphine in serum by radioimmunoassay. J Pharm Exp Ther 178 (1971) 253-258
57. St Clair Roberts J., Akers C.V., Vanhinsbergh L., et al. Longitudinal safety and immunogenicity data of TA-NIC, a novel nicotine vaccine. Proceedings of the 9th Annual Meeting of the Society for Research on Nicotine and Tobacco (2003), Society for Reserach on Nicotine and Tobacco, New Orleans, LA Feb 19-22, 2003
58. Tuncok Y., Hieda Y., Keyler D.E., et al. Inhibition of nicotine-induced seizures in rats by combining vaccination against nicotine with chronic nicotine infusion. Exp Clin Psychopharmacol 9 (2001) 228-234
59. U.S. Department of Health and Human Services Center for Disease Control and Prevention. Retrieved June 30, 2008, from http://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/cessation2.htm.
60. US Substance Abuse and Mental Health Services Administration. Results from the 2007 National Survey on Drug Use and Health: National Findings (2008), Office of Applied Studies, Rockville, MD NSDUH Series H-34, DHHS Publication No. SMA 08-4343
61. Withers N.W., Pulvirenti L., Koob G.F., and Gillin J.C. Cocaine abuse and dependence. J Clinical Psychopharmacol 15 (1995) 63-78
62. Yang G., Chun J., Arakawa-Uramoto H., et al. Anti-cocaine catalytic antibodies: a synthetic approach to improve antibody diversity. J Am Chem Soc 118 (1996) 5881-5890
63. Zheng F., Yang W., Ko M.C., Liu J., Cho H., Gao D., et al. Most efficient cocaine hydrolase designed by virtual screening of transistion states. J Am Chem Soc 130 (2008) 12148-12155